Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

Feature Video
A lung cancer survivor shares her story of understanding her complex disease and finding a treatment plan to match.
A lung cancer survivor shares her story of understanding her complex disease and finding a treatment plan to match.
Treatments with PARP inhibitors and immunotherapies are helping patients with small cell lung cancer live better and longer.
Immunotherapy and stereotactic radiation are making a difference for some patients with advanced lung cancer.
Brielle Urciuoli
Two women discuss their experience in cancer caregiving, while giving advice to others.
Jessica Skarzynski
Given their proximity to both patients and information, lung cancer advocacy groups are in a good position to help better educate patients and physicians about the benefits of biomarker testing.
Katie Kosko
Lock Up Lung Cancer is a new campaign to expose the disease as a prolific killer, according to LUNG FORCE.
Katie Kosko
Many patients with lung cancer may experience side effects, such as fatigue and shortness of breath, that can prevent them from exercising. However, for the first time, new research findings showed benefits from exercise in those with advanced disease.
Brielle Urciuoli
Promising results from a recent trial are laying the groundwork for the first change in frontline small cell lung cancer in two decades.
CRISPR technology can edit the genetic code of most living things. How will it be used to prevent and treat cancer, and what are the ethical considerations?
Brielle Urciuoli and Kristie L. Kahl
The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other